Published in:
01-02-2019 | Concise Research Reports
Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries
Authors:
Partik Singh, BA, Howard Forman, MD, MBA, Adewole S. Adamson, MD, MPP, Arash Mostaghimi, MD, MPA, MPH, Alexis R. Ogdie, MD, MSCE, Arman Oganisian, MS, John S. Barbieri, MD, MBA
Published in:
Journal of General Internal Medicine
|
Issue 2/2019
Login to get access
Excerpt
Industry payments (including in-kind) to physicians in the form of attendance of industry sponsored continuing medical education, gifts, and meals are associated with increased rates of prescription of higher-cost, branded medications.
1‐4 Whether industry payments are associated with preferential prescribing within a single class of brand medications is uncertain. We conducted a cross-sectional study to examine the association between industry payments and prescribing patterns for the branded tumor necrosis factor (TNF) inhibitors etanercept and adalimumab, which are in the same therapeutic class and have similar clinical indications. …
